Loading page
Loading page
Loading substance route
Weak oral bioavailability; individual response highly unpredictable. Onset varies with stomach contents.
Effects vary widely by individual, dose, and context.
At light to moderate doses, there is often a slight sense of anaesthetization and relaxation. As the dose increases, perceptions of heart rate increase and body tremors and loss of muscle control are often reported. DPT can range from strong euphoria and erotiscism to nausea and dysphoria even within the same trip.
DPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
DPT is not habit-forming and the desire to use it can actually decrease with use. As with most psychedelics, it is reported to be self-limiting.
No physical dependence or withdrawal symptoms have been documented. The substance is reported to be self-limiting like other psychedelic tryptamines.
The exact toxic dose is unknown and thorough toxicological evaluation is lacking. One alleged death occurred in Minnesota in 2015, though the role of DPT was not confirmed. Another death has been associated with DPT and seizures, though the dose involved is unknown. The pharmacological similarity to DMT suggests generally low intrinsic toxicity at controlled doses, but synthetic tryptamine analogues lack the well-characterized safety profile of classical psychedelics.
There is some potential for temporary psychosis during the experience. Transient anxiety and paranoia are more commonly reported adverse psychological effects. The substance is considered more psychologically challenging than many other psychedelics, with experiences often described as 'bizarre' and 'unsettling.' Those with existing psychiatric disorders should avoid this substance.
One death has been associated with DPT and seizures, though the dose is unknown. Animal research indicates complex dose-dependent effects: at lower doses DPT demonstrated anticonvulsant properties in mouse models, while at higher doses it switched to proconvulsant action. Psychedelics may act as triggers for seizures in predisposed individuals.
DPT was first synthesized in 1950, with initial pharmacological testing conducted in dogs by 1954. The compound was formally described in scientific literature by 1959, and human trials during the 1960s confirmed its hallucinogenic properties. By 1968, DPT had been identified as a novel designer
Listed in Belgium's most restrictive controlled substance category, approximately equivalent to Schedule II under the United States system. Manufacturing, distribution, and possession are prohibited.
Became a controlled substance on February 18, 2003 under national drug legislation.
Classified as a Schedule I controlled substance under national drug legislation. Possession, distribution, and production are illegal.
Listed in Table II-A of the controlled substances tables alongside substances such as MDMA and LSD. Production and trafficking remain illegal; personal possession of small quantities is decriminalized under Portuguese drug policy.
Specifically named as a controlled substance under Verzeichnis E (Schedule E) of Swiss narcotics legislation. Unauthorized possession, production, and distribution are prohibited.
DPT remains unscheduled at the federal level, meaning possession, purchase, and distribution are generally legal under federal law. However, several states have independently scheduled the substance: Florida classifies it as Schedule I, Maine lists it as Schedule X, and Oklahoma has placed it in Schedule I. The Federal Analogue Act may apply if sold for human consumption.
Controlled under the New Psychoactive Substances Act as of July 18, 2019. Production and importation with intent to market, administration to others, and trading are criminally punishable. Possession is prohibited but not subject to criminal penalty.
Controlled under the Pharmaceutical Affairs Law. Possession and sale are prohibited.
Controlled as a Class C substance due to its structural relationship to DMT, which is explicitly scheduled. The analogue provisions extend control to structurally similar tryptamines.
Classified as a narcotic substance on January 26, 2016 following its sale as a designer drug. Manufacturing, trade, and possession are prohibited.
Controlled under the Misuse of Drugs Act 1971 through the tryptamine catch-all clause, which covers compounds structurally derived from tryptamine by substitution at the nitrogen atom of the sidechain with alkyl substituents. Class A classification carries the most severe penalties for possession, production, and distribution.
13 sources cited
